24.76
-0.36 (-1.43%)
| Previous Close | 25.12 |
| Open | 25.12 |
| Volume | 287,336 |
| Avg. Volume (3M) | 2,060,496 |
| Market Cap | 2,569,634,304 |
| Price / Sales | 70.43 |
| Price / Book | 6.67 |
| 52 Weeks Range | |
| Earnings Date | 8 Oct 2026 |
| Operating Margin (TTM) | -340.67% |
| Diluted EPS (TTM) | -2.60 |
| Quarterly Revenue Growth (YOY) | 11.30% |
| Total Debt/Equity (MRQ) | 5.54% |
| Current Ratio (MRQ) | 6.26 |
| Operating Cash Flow (TTM) | -191.72 M |
| Levered Free Cash Flow (TTM) | -106.56 M |
| Return on Assets (TTM) | -31.08% |
| Return on Equity (TTM) | -64.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Nurix Therapeutics, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -5.0 |
| Price Volatility | -3.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | -0.75 |
|
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.41% |
| % Held by Institutions | 111.85% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HANSEN GWENN | - | 24.46 | -12,314 | -301,636 |
| RING CHRISTINE | - | 23.40 | -20,436 | -475,909 |
| VAN HOUTE HANS | - | 24.14 | -7,606 | -184,634 |
| Aggregate Net Quantity | -40,356 | |||
| Aggregate Net Value ($) | -962,179 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 24.07 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HANSEN GWENN | Officer | 05 Aug 2026 | Automatic sell (-) | 4,356 | 25.12 | 109,423 |
| HANSEN GWENN | Officer | 05 Aug 2026 | Option execute | 4,356 | - | - |
| VAN HOUTE HANS | Officer | 04 Aug 2026 | Automatic sell (-) | 4,761 | 24.69 | 117,549 |
| HANSEN GWENN | Officer | 04 Aug 2026 | Automatic sell (-) | 4,111 | 24.69 | 101,501 |
| RING CHRISTINE | Officer | 03 Aug 2026 | Automatic sell (-) | 16,589 | 23.22 | 385,197 |
| RING CHRISTINE | Officer | 03 Aug 2026 | Option execute | 5,787 | - | - |
| HANSEN GWENN | Officer | 30 Jul 2026 | Sell (-) | 3,847 | 23.58 | 90,712 |
| HANSEN GWENN | Officer | 30 Jul 2026 | Option execute | 10,180 | - | - |
| RING CHRISTINE | Officer | 30 Jul 2026 | Sell (-) | 3,847 | 23.58 | 90,712 |
| RING CHRISTINE | Officer | 30 Jul 2026 | Option execute | 10,180 | - | - |
| VAN HOUTE HANS | Officer | 30 Jul 2026 | Sell (-) | 2,845 | 23.58 | 67,085 |
| VAN HOUTE HANS | Officer | 30 Jul 2026 | Option execute | 10,180 | - | - |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |